Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Subcutaneous Elafin in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03522935
Recruitment Status : Completed
First Posted : May 14, 2018
Last Update Posted : April 28, 2021
Sponsor:
Collaborators:
Duke University
SRI International
Information provided by (Responsible Party):
Roham T. Zamanian, Stanford University

Brief Summary:
A multiple-ascending-dose (MAD), randomized, placebo-controlled, blinded trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Elafin in healthy adult subjects. The purpose of this study is to assess Elafin that is being developed for treatment of PAH. Elafin inhibits elastase, an enzyme that is increased in pulmonary hypertension and is a major factor in the development of PAH. Elafin will be administered subcutaneously daily for 7 days in normal healthy subjects followed over a 28 day time period.

Condition or disease Intervention/treatment Phase
Pulmonary Arterial Hypertension Drug: Elafin Drug: Placebo Phase 1

Detailed Description:

There will be a total of up to 30 subjects randomly assigned to 5 groups with 6 subjects in each group. One subject in each group will be assigned to placebo drug and 5 subjects to active drug. Subjects in each group will receive a single daily dose of Elafin/Placebo for total of 7 days. There will be ascending doses across groups. Groups receiving a higher dose will only do so after the previous group has completed dosing (i.e., 7 days). Each subject will be followed over a 28 day time period.

An interim trial analysis will occur after completion of the 2nd cohort in order for the research team to review PK and safety data to determine modification (if needed) of dosing strategy for groups 3-5. The study is also designed to absorb a de-escalation strategy. If the protocol requires a lowering of dose from the initial dosing, a new group will be assigned a low-dose subcutaneous Elafin regimen.

The study will conclude at any dose that produces clinically significant adverse effects and identified as Maximum Tolerated Dose (MTD).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: Safety and Tolerability of Escalating Doses of Subcutaneous Elafin (Tiprelestat) Injection in Healthy Normal Subjects
Actual Study Start Date : March 18, 2019
Actual Primary Completion Date : October 25, 2019
Actual Study Completion Date : November 18, 2020


Arm Intervention/treatment
Experimental: Elafin 0.03 mg/kg
5 subjects will be administered with 0.03 mg/kg of Elafin subcutaneously once daily for 7 days.
Drug: Elafin
Elafin subcutaneous.
Other Name: Tiprelestat

Experimental: Elafin 0.06 mg/kg
5 subjects will be administered with 0.06 mg/kg of Elafin subcutaneously once daily for 7 days.
Drug: Elafin
Elafin subcutaneous.
Other Name: Tiprelestat

Experimental: Elafin 0.10 mg/kg
5 subjects will be administered with 0.10 mg/kg of Elafin subcutaneously once daily for 7 days.
Drug: Elafin
Elafin subcutaneous.
Other Name: Tiprelestat

Experimental: Elafin 0.15 mg/kg
5 subjects will be administered with 0.15 mg/kg of Elafin subcutaneously once daily for 7 days.
Drug: Elafin
Elafin subcutaneous.
Other Name: Tiprelestat

Experimental: Elafin 0.18 mg/kg
5 subjects will be administered with 0.18 mg/kg of Elafin subcutaneously once daily for 7 days.
Drug: Elafin
Elafin subcutaneous.
Other Name: Tiprelestat

Placebo Comparator: Placebo Drug
5 subjects will be administered with placebo drug subcutaneously once daily for 7 days.
Drug: Placebo
Placebo subcutaneous.




Primary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events in healthy controls. [ Time Frame: 28 day time period ]
    Safety and tolerability will be determined on the basis of adverse events reported and the severity of adverse events.


Secondary Outcome Measures :
  1. Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: AUC0-last [ Time Frame: 28 day time period ]
    AUC0-last: Area under the concentration time-curve to the last concentration above the lower limit of quantitation (after final dose consumed)


Other Outcome Measures:
  1. Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: Cmax [ Time Frame: 28 day time period ]
    Cmax: Maximum observed concentration

  2. Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: Tmax [ Time Frame: 28 day time period ]
    Tmax: Time of maximum observed concentration

  3. Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: Ke [ Time Frame: 28 day time period ]
    Ke: Elimination rate constant

  4. Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: AUC0-inf [ Time Frame: 28 day time period ]
    AUC0-inf: Area under the concentration time-curve extrapolated to infinit

  5. Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: t½ [ Time Frame: 28 day time period ]
    t½: Terminal elimination half-life

  6. Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: CL/F [ Time Frame: 28 day time period ]
    CL/F: Apparent total clearance of the drug from plasma after oral administration

  7. Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: V/F [ Time Frame: 28 day time period ]
    V/F: Oral volume of distribution



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

A subject will be eligible only if all of the following criteria apply:

  1. Male or female, 18 - 55 years of age
  2. No history or clinically relevant cardiovascular, renal, gastrointestinal, hepatic, metabolic, endocrine, neurological, or psychiatric abnormalities and is in general good health at screening examination.
  3. Normal or clinically acceptable ECG
  4. Normal blood pressure (systolic: 90 - 140 mmHg; diastolic: 50 - 90 mmHg) and heart rate (45 - 100 bpm)
  5. Body mass index of 18.0 - 32.0 (kg/m2)
  6. Ability to communicate well with the investigator and to comply with the requirements of the entire study.
  7. Informed consent.
  8. Females of childbearing potential must use an acceptable form of contraception at time of enrollment (and throughout the duration of study) including, but not limited to the following:

    1. Documentation of surgical sterilization (bilateral tubal ligation, hysterectomy)
    2. Naturally postmenopausal (spontaneous cessation of menses) for at least 24 consecutive months prior to dosing on Day -1 and with an FSH level at screening of ≥ 40 mIU/mL
    3. Intrauterine Device (IUD) plus condom plus contraceptive sponge or foam or jelly
    4. Condom plus contraceptive sponge or foam or jelly
    5. Hormonal contraception (combination oral contraceptives, transdermal patch, injectables, implantables, or vaginal ring) *Subject is not of childbearing potential if the following criteria have been met:
    1. Hysterectomy > 1 month ago
    2. Bilateral oophorectomy > 1 month ago
    3. 45-50 years old AND LMP ≥ 24 months ago and documented FSH > 40mIU/mL
  9. Males must agree to use a barrier method of birth control from 30 days before first study drug administration until 90 days after last study drug administration.

Exclusion criteria:

A subject will not be eligible if any of the following criteria apply:

  1. Administration of any investigational drug 45 days prior to study enrollment.
  2. Active participation in another interventional clinical trial.
  3. Use of any prescription medication within 30 days (with exception to oral contraceptives) or over-the-counter medication (OTC) within 7 days before first study drug administration. Use of OTC medications may be permitted after day 1 visit until end of study with approval of the protocol investigator.
  4. Subject performed heavy physical exertion 2 days before eligibility assessment and before admission into clinical research center.
  5. Subject consumes more than 500 mL of beer/day or 250 mL of wine/day or 2 glasses of liquor/day.
  6. Subject has a history of chronic alcohol or drug abuse within the last 4 weeks.
  7. Subject smokes more than 10 cigarettes per day or has done so within 6 months prior to eligibility assessment.
  8. Subject has a diet that deviates notably from the "normal" amounts of protein, carbohydrate, and fat, as judged by the investigator (e.g., vegetarians or vegans).
  9. Subject consumes more than 600 mg of caffeine/day (200 mL of coffee contain approximately 100 mg of caffeine, 200 mL of black tea approximately 30 mg and 200 mL of soda approximately 20 mg).
  10. Subject has donated blood or had a comparable blood loss (>400 mL) within the last 3 months prior to eligibility assessment or anemia defined by hematocrit value less than 30% at screening.
  11. Subject has any clinically relevant abnormality in physical examination, vital signs and electrocardiogram (ECG).
  12. Serious adverse reaction or hypersensitivity to any drug.
  13. Inability to communicate or co-operate due to a language problem, poor mental development or impaired cerebral function.
  14. Females who are lactating or at risk of pregnancy.
  15. Presence of pain incurred by unknown causes.
  16. History of asthma or other respiratory disease.
  17. History of neurologic or neuromuscular disease.
  18. History of hypotension, hypertension or cardiovascular disease.
  19. History of gastrointestinal, hepatic, or renal disease and/or impairment.
  20. Positive urine drug screen for drugs with a high potential for abuse and low persistence in the urine.
  21. Subject with active or history of malignancy, known Hepatitis B or C, or HIV.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03522935


Locations
Layout table for location information
United States, North Carolina
Duke Early Phase Research Unit (DEPRU)
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Roham T. Zamanian
Duke University
SRI International
Investigators
Layout table for investigator information
Principal Investigator: Roham Zamanian, MD Stanford University
Layout table for additonal information
Responsible Party: Roham T. Zamanian, Associate Professor, Stanford University
ClinicalTrials.gov Identifier: NCT03522935    
Other Study ID Numbers: 42336
First Posted: May 14, 2018    Key Record Dates
Last Update Posted: April 28, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Arterial Hypertension
Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases
Elafin
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action